A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

Inclusion Criteria:

• Signed informed consent;

• Patients with CTCL who do not respond well to targeted skin therapy (topicalcorticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA)and advanced stage (stage IIB-IV);

• Age 18-75 years;

• Expected survival time greater than 3 months (follow-up for the historical controlgroup was greater than 3 months);

Exclusion Criteria:

• Received other anti-tumor therapy other than skin-targeted therapy (phototherapy,topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;

• Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;

• Combined with other malignant tumors, still receiving anti-tumor therapy;

• Has any other active disease that may increase the risk of protocol therapy orimpair the patient's ability to receive protocol therapy, including butnot limited to:

• Comorbid epilepsy;

• Comorbid autoimmune diseases;

• Combined with hepatic decompensation;

• Patients with renal insufficiency and creatinine clearance < 50ml/min;

• Have an uncontrollable medical condition, including but not limited to:

• Ongoing or active infection;

• Clinically significant healing or non-healing wounds;

• Symptomatic congestive heart failure, unstable angina, clinically significantarrhythmias;

• Significant lung disease (e.g., shortness of breath at rest or light activity,or need for supplemental oxygen for any reason);

• Diseases/conditions that affect study compliance, such as infectious diseasesor psychiatric illnesses/social situations, that are uncontrollable;

• Pregnant (or intending to become pregnant within 2 years) or lactating females;

• Concomitant participation in interventional clinical trials of other clinical trialdrugs, except for questionnaire surveys or observational studies;

• Any situation in which the programme is not in compliance;

• Other conditions that in the opinion of the investigator are not suitable forparticipation in this study.